BioSpace News Archive

The report provides details about market size, market restraints, drivers, challenges, growth opportunities, and top companies in the market. The report also highlights about changes in the market dynamics due to outbreak of the COVID-19 pandemic.

Navidea Biopharmaceuticals, Inc. today welcomed Kenneth Berger, Ph.D., as Senior Regulatory Consultant, and the return of the Company’s former Director of Regulatory Affairs, Richard McFerron.

Bolt Biotherapeutics announced that management will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022, at 12:45 p.m. PT.

Impel NeuroPharma announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022 at 1:30 p.m. ET.

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 3rd, 2022.

Funding used to boost development and start clinical trials in humans in 2023.

Inventiva announced that the abstract “Lanifibranor, a pan-PPAR agonist, improves markers of cardiometabolic health in patients with NASH” has been selected for oral presentation during the third International Conference on Fatty Liver to be held from the 28th to the 30th of April 2022 in Vienna, Austria.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following investor conferences in April.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 12:45 p.m. PT / 3:45 p.m. ET.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the first quarter ended February 28, 2022 and provided a corporate update.